Defilade Capital Management, L.P. Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0002088557
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q3 2026 · 30 positions · Total reported value $598.80M · Top-10 concentration 54.9% · Updated 2026-11-17
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
Turnover: 76.6% · 8 new · 11 cut · 17 exited
Active Share (vs S&P 500): 96.9% · vs QQQ: 97.8% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q2 2026 → Q3 2026): +0.3% · vs SPY -1.8% · Prev Value $746.95M — last quarter positions weighted by this quarter price moves · ranking
Est. QTD Return (Q3 2026 → newest close): +0.1% · vs SPY -2.1% · Latest Value $598.80M — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking
In its Q3 2026 13F filing, Defilade Capital Management, L.P. disclosed 30 equity positions with a combined reported value of $598.80M. The filing implies a moderately concentrated portfolio: its ten largest positions account for 54.9% of reported value. HoldingsHub classifies the profile as Small / Health Tilt / High Turnover.
The largest disclosed positions as of Q3 2026 were PFE ($43.49M), LLY ($40.24M), BMRN ($36.12M). By sector, the heaviest allocations are Health Care 93.7%, Technology 3.3%. Versus the prior quarter, allocation shifted toward Health Care (+4.0pp) and away from Industrials (-0.5pp), Other (-1.2pp).
Versus the prior quarter, Defilade Capital Management, L.P. opened 8 new positions, trimmed 11 and fully exited 17, a turnover rate of 76.6% of positions. The portfolio's overlap with the prior quarter was 47% of names.
The largest new positions opened in Q3 2026 were GILD ($33.77M), AXSM ($32.34M), AMGN ($31.23M).
Of the 17 positions fully exited versus the prior quarter, the largest were PTCT ($35.38M), BAX ($31.11M), INSM ($30.05M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q3 2026)
Fully Exited (vs previous quarter)
- PTCT PTC THERAPEUTICS INC · prev qtr: $35.38M
- BAX BAXTER INTL INC · prev qtr: $31.11M
- INSM INSMED INC · prev qtr: $30.05M
- ZBH ZIMMER BIOMET HOLDINGS INC · prev qtr: $27.33M
- PODD INSULET CORP · prev qtr: $26.94M
- ABT ABBOTT LABORATORIES · prev qtr: $25.93M
- MDT MEDTRONIC PLC · prev qtr: $23.73M
- ELAN ELANCO ANIMAL HEALTH INC · prev qtr: $21.27M
Insider Transactions (Form 4)
Latest Defilade Capital Management, L.P. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.
Fund Profile
Defilade Capital Management, L.P. is an SEC-registered 13F filer based in Emeryville, CA, United States. As of Q3 2026 it reported 30 US equity positions with a combined value of $598.80M. HoldingsHub carries 4 quarters of its filings (Q4 2025–Q3 2026).
Firm Snapshot
- Headquarters: EMERYVILLE, CA, United States
- SEC registration: 801-134248 (status: Approved), registered 2025-08-27
- Regulatory AUM (Form ADV): $1.55B as of 2026-06-26
- Client mix (by RAUM): pension and profit-sharing plans 100%
- Manages 1 private funds, of which 1 hedge funds
- Website: defcap.com
Portfolio Structure
- 30 positions · $598.80M reported value (Q3 2026)
- Top 10 holdings = 54.9% of reported value
- Largest position: PFE (PFIZER INC) at 7.3%
- Average position size: $19.96M
Sector Tilt
- Health Care 93.7%
- Information Technology 3.3%
- Industrials 3.0%
- (classified holdings cover 100% of value)
Quarterly Activity
- Q3 2026: 8 new, 9 added, 11 reduced, 17 exited
- 2 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
1.52M | $43.49M | 7.26% | Reduce | |
| 2 |
|
34.77K | $40.24M | 6.72% | Reduce | |
| 3 |
|
601.92K | $36.12M | 6.03% | Reduce | |
| 4 |
|
226.57K | $33.77M | 5.64% | New | |
| 5 |
|
175.37K | $32.34M | 5.40% | New | |
| 6 |
|
74.08K | $31.23M | 5.21% | New | |
| 7 |
|
2.27M | $30.61M | 5.11% | Add | |
| 8 |
|
128.86K | $29.36M | 4.90% | Add | |
| 9 |
|
71.86K | $29.22M | 4.88% | New | |
| 10 |
|
81.52K | $22.45M | 3.75% | New | |
| 11 |
|
652.38K | $21.07M | 3.52% | New | |
| 12 |
|
631.64K | $20.23M | 3.38% | Add | |
| 13 |
|
69.14K | $19.74M | 3.30% | Reduce | |
| 14 |
|
332.20K | $19.39M | 3.24% | New | |
| 15 |
|
570.32K | $18.96M | 3.17% | Add | |
| 16 |
|
26.47K | $17.87M | 2.98% | Reduce | |
| 17 |
|
2.28M | $17.45M | 2.92% | Add | |
| 18 |
|
4.93M | $15.77M | 2.63% | Add | |
| 19 |
|
350.78K | $15.31M | 2.56% | New | |
| 20 |
|
71.19K | $14.61M | 2.44% | Reduce | |
| 21 |
|
165.67K | $14.60M | 2.44% | Reduce | |
| 22 |
|
534.43K | $12.54M | 2.10% | Reduce | |
| 23 |
|
1.44M | $12.44M | 2.08% | Add | |
| 24 |
|
1.43M | $11.82M | 1.97% | Add | |
| 25 |
|
3.53M | $8.92M | 1.49% | Hold | |
| 26 |
|
54.44K | $8.74M | 1.46% | Reduce | |
| 27 |
|
399.65K | $7.30M | 1.22% | Reduce | |
| 28 |
|
164.98K | $6.86M | 1.15% | Reduce | |
| 29 |
|
1.77M | $3.34M | 0.56% | Add | |
| 30 |
|
7.56M | $3.04M | 0.51% | Hold | |
FAQ
What did Defilade Capital Management, L.P. buy in 2026-Q3?
In its 2026-Q3 13F filing, Defilade Capital Management, L.P. reported 30 equity positions worth $598.80M in aggregate; its largest disclosed positions were PFE ($43.49M), LLY ($40.24M), BMRN ($36.12M).
How large is Defilade Capital Management, L.P.'s portfolio?
Defilade Capital Management, L.P. reported $598.80M of long equity holdings across 30 positions as of 2026-Q3. Top-10 holdings account for 54.9% of reported value.
What is Defilade Capital Management, L.P.'s investment style?
HoldingsHub classifies the portfolio as Small / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.